FDA Welcomes AI Advancements with Launch of New Tool ‘Elsa’

The FDA has introduced “Elsa,” a generative AI tool aimed at enhancing its operations by improving efficiency for employees like scientific reviewers and investigators. Announced ahead of schedule and under budget, Elsa was developed following a successful pilot and is built within a secure GovCloud environment to safeguard sensitive information. The tool is utilized for various functions, including accelerating clinical protocol reviews, summarizing adverse event reports, and prioritizing inspections, ultimately streamlining regulatory decision-making. FDA Chief AI Officer Jeremy Walsh emphasized that Elsa marks the beginning of a new AI era, with plans for ongoing capability enhancements based on employee feedback. Despite its advantages, the implementation of AI in federal agencies like the FDA poses risks, including bias, privacy concerns, and potential overreliance on automated systems, highlighting the need for careful monitoring and responsible governance to balance innovation with public trust.

Source link